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Objective: Birth weight (BW) is thought to be determined by maternal health, genetic, nutritional and placental factors; the latter is influenced by anatomical development and perfusion. Maternal cardiovascular changes contribute to utero-placental perfusion, however have not been investigated in relation to fetal growth/BW. We explored the relationship between maternal cardiovascular adaptation, fetal growth and BW in healthy pregnancies.
Methods: We conducted a longitudinal prospective study of 143 women planning to conceive. Maternal cardiac output (CO), cardiac index (CI), pulse wave velocity, aortic augmentation index (AIx), central blood pressure and peripheral vascular resistance (PVR) were assessed prior to pregnancy and at 6, 23 and 33 weeks gestation. Fetal growth was assessed using serial ultrasound biometry.
Results: There were 64 live births with normal pregnancy outcome. We report positive correlations between BW and pre-pregnancy to second trimester changes in CO (ρ = 0.4, P = 0.004), CI (ρ = 0.3, P = 0.02) and PVR (ρ = 0.3, P = 0.02). There was a significant association between pre-pregnancy to second trimester increase in CO (: 0.8 ± 1.2 L/min; ρ = 0.3, P = 0.02), CI (: 0.4 ± 0.6; ρ = 0.3, P = 0.04), and reduction in AIx (:-10± 9%; ρ = 3, P = 0.04) with third trimester ultrasound-estimated fetal weight gain. 
Conclusions: In healthy pregnancy, third trimester fetal growth and BW are associated with incremental maternal CO change in early pregnancy. It is plausible this association is causative, as changes predate third trimester fetal growth and eventual BW.







Birth weight (BW) is an important factor influencing neonatal, infant and childhood morbidity and mortality. A fetus with an estimated weight (EFW) below the 3rd percentile, or those with a combination of EFW below the 10th percentile and abnormal umbilical artery blood flow are more likely to suffer from adverse perinatal outcome such as cerebral palsy compared to fetuses of appropriate weight for gestation ADDIN EN.CITE ,. Moreover, the ‘Barker hypothesis’ suggests a link between low BW and cardiovascular disease in adulthood ADDIN EN.CITE 3. 
Abnormally high uterine artery Doppler impedance is thought to reflect sub-optimal utero-placental perfusion and is strongly linked to compromised fetal growth. This has led to the hypothesis that placental function determines fetal growth. However, uterine artery flow is also influenced by maternal haemodynamics such as plasma volume and cardiac output (CO). Prospective studies in early pregnancy have reported changes in maternal brachial blood pressure (bSBP), heart rate (HR) and CO as early as 5 weeks (one week after embryonic implantation) in normal pregnancies. ADDIN EN.CITE 4-7 These changes plateau in the second or third trimester before returning to baseline values in the postpartum period. ADDIN EN.CITE , 
Low maternal CO, insufficient volume expansion and high peripheral vascular resistance (PVR) may predate fetal growth restriction (FGR). ADDIN EN.CITE 9-11 In pregnancies complicated by pre-eclampsia (new-onset hypertension after 20 weeks gestation and proteinuria in pregnancy), maternal CO in the first trimester is lower in women who subsequently had growth restricted babies ADDIN EN.CITE 12. Thus, adequate maternal cardiovascular adaptation may be necessary for optimal uteroplacental perfusion and fetal growth ADDIN EN.CITE 13. The relationship between longitudinal maternal cardiovascular changes from prior to pregnancy and fetal growth and BW in normal pregnancies has not previously been described. Understanding the magnitude and timing of these changes in normal pregnancy may clarify the role of cardiovascular maladaptation in syndromes hitherto ascribed to primary uteroplacental insufficiency: namely FGR and pre-eclampsia.
We investigated maternal cardiovascular adaptation from prior to conception to mid-pregnancy in association with fetal growth trajectories and BW in normal pregnancies. 

Methods
This study was designed as a prospective feasibility study of recruitment and completion of follow-up for investigating maternal cardiovascular function from preconception to postpartum. The study was conducted at a single tertiary referral centre. The study received Local Research Ethics Committee and Research and Development on-site approval.
Recruitment
Recruitment was achieved by advertisements over a period of 11 months from July 2010 to June 2011. Study posters were put up in the hospital where the study was based, in GP surgeries in Cambridgeshire, on the hospital website, local newspapers, preschool groups, and National Childbirth Trust newsletters. The advertisements had the contact details of the lead research fellow and women who were interested to participate could contact the research fellow by phone or email. In addition, contact details of women who have had previous adverse obstetric history such as pre-eclampsia, FGR or recurrent miscarriage (RM) were also obtained from the delivery and recurrent miscarriage clinic database of the hospital in which the study was based.  

The study inclusion criteria were: nulliparous women, multiparous women with previous normal pregnancies, previous preeclampsia and/or FGR and previous unexplained RM, between 18–50 years of age. Preeclampsia was defined by the criteria laid by the International Society for the Study of Hypertension in Pregnancy HYPERLINK \l "_ENREF_14" \o "Davey, 1988 #9"  ADDIN EN.CITE <EndNote><Cite><Author>Davey</Author><Year>1988</Year><RecNum>9</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="eszedrza7x02a6e9vz2vsew859ppse5adtwz" timestamp="1443617208">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Davey, D. A.</author><author>MacGillivray, I.</author></authors></contributors><auth-address>Department of Obstetrics and Gynaecology, University of Cape Town Medical School, South Africa.</auth-address><titles><title>The classification and definition of the hypertensive disorders of pregnancy</title><secondary-title>Am J Obstet Gynecol</secondary-title><alt-title>American journal of obstetrics and gynecology</alt-title></titles><periodical><full-title>Am J Obstet Gynecol</full-title><abbr-1>American journal of obstetrics and gynecology</abbr-1></periodical><alt-periodical><full-title>Am J Obstet Gynecol</full-title><abbr-1>American journal of obstetrics and gynecology</abbr-1></alt-periodical><pages>892-8</pages><volume>158</volume><number>4</number><keywords><keyword>Diagnosis, Differential</keyword><keyword>Eclampsia/classification/diagnosis</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hypertension/diagnosis</keyword><keyword>Pre-Eclampsia/*classification/diagnosis</keyword><keyword>Pregnancy</keyword><keyword>Prognosis</keyword><keyword>Proteinuria/diagnosis</keyword><keyword>Terminology as Topic</keyword></keywords><dates><year>1988</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0002-9378 (Print)&#xD;0002-9378 (Linking)</isbn><accession-num>3364501</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/3364501</url></related-urls></urls></record></Cite></EndNote>14 .  FGR was defined as birth weight below third percentile ADDIN EN.CITE 15, in the absence of congenital infection or aneuploidy. Unexplained RM was defined as more then three consecutive miscarriages at <12 weeks, gestation where investigations such as thrombophilia screen, cytogenetic examination of products of conception, pelvic ultrasound and parental peripheral blood karyotyping were negative and no specific problem was detected. The exclusion criteria were smokers, history of thrombophilia (Protein S or C deficiency, Antithrombin II deficiency, positive lupus anticoagulant) or diabetes. 

In total, 184 women expressed their interest in participating in the study. Of this, 143 women met the eligibility criteria and consented to participate (see Figure 1 for recruitment flowchart).
Study protocol
The study protocol is described in Figure 2. Women were recruited prior to conception and had baseline cardiovascular assessments as described below. They then performed digital home urine ovulation tests and pregnancy tests as described in Figure 2. The day of ovulation was estimated by adding one day to the day luteinizing hormone surge was detected. The day of the first positive pregnancy test using sensitive digital urine pregnancy test kits was reported as the implantation day. Women who became pregnant were then followed up with serial ultrasound scans and repeat cardiovascular assessments in very early pregnancy, in second and third trimester and 3–4 months postpartum. Women who did not get pregnant at the end of the 6 cycles or who suffered either miscarriage or ectopic pregnancy but wanted to continue with the study were recruited back into the study. Their baseline cardiovascular assessments were not repeated.
Cardiovascular assessment
Cardiovascular measurements were performed after 10 min rest in the supine left lateral position. Participants were requested to abstain from caffeinated drinks for 4 hours prior to their visit. Brachial blood pressure (BP) and heart rate were measured in the non-dominant arm using an automated blood pressure measuring device (Omron-M7) that has been validated for use in pregnancy HYPERLINK \l "_ENREF_16" \o "de Greeff, 2009 #11"  ADDIN EN.CITE <EndNote><Cite><Author>de Greeff</Author><Year>2009</Year><RecNum>11</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="eszedrza7x02a6e9vz2vsew859ppse5adtwz" timestamp="1443617448">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>de Greeff, A.</author><author>Beg, Z.</author><author>Gangji, Z.</author><author>Dorney, E.</author><author>Shennan, A. H.</author></authors></contributors><auth-address>Maternal and Fetal Research Unit, King&apos;s College London and Division of Reproduction and Endocrinology, St Thomas&apos; Hospital, London, UK.</auth-address><titles><title>Accuracy of inflationary versus deflationary oscillometry in pregnancy and preeclampsia: OMRON-MIT versus OMRON-M7</title><secondary-title>Blood Press Monit</secondary-title><alt-title>Blood pressure monitoring</alt-title></titles><periodical><full-title>Blood Press Monit</full-title><abbr-1>Blood pressure monitoring</abbr-1></periodical><alt-periodical><full-title>Blood Press Monit</full-title><abbr-1>Blood pressure monitoring</abbr-1></alt-periodical><pages>37-40</pages><volume>14</volume><number>1</number><keywords><keyword>Adult</keyword><keyword>Blood Pressure Determination/*instrumentation/standards</keyword><keyword>Female</keyword><keyword>Great Britain</keyword><keyword>Humans</keyword><keyword>Observer Variation</keyword><keyword>Oscillometry/*instrumentation</keyword><keyword>Pre-Eclampsia/*physiopathology</keyword><keyword>Pregnancy</keyword></keywords><dates><year>2009</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1473-5725 (Electronic)&#xD;1359-5237 (Linking)</isbn><accession-num>19252437</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/19252437</url></related-urls></urls><electronic-resource-num>10.1097/MBP.0b013e32831e305d</electronic-resource-num></record></Cite></EndNote>16, using standard cuff sizes according to the arm circumference of the participant. Radial artery waveforms were obtained with a high-fidelity micromanometer (SPC-301; Millar Instruments, Houston, TX, USA) from the wrist, and a corresponding central waveform was generated with a validated transfer function (SphygmoCor; AtCor Medical, Sydney, Australia) as previously described ADDIN EN.CITE 17-19. Central systolic BP, mean arterial pressure and aortic augmentation index were determined using the integrated software. Aortic stiffness was assessed by measuring the carotid-femoral (aortic) pulse wave velocity with the same device ADDIN EN.CITE 20. The carotid-femoral distance was measured using calipers. 

Cardiac output was assessed using a non-invasive, inert gas re-breathing technique (Innocor, Innovision A/S, Odense S, Denmark), which has previously been validated against thermodilution  ADDIN EN.CITE 21-23 and direct Fick  ADDIN EN.CITE , methods for measurement of pulmonary blood flow and thus, cardiac output. Reproducibility of this technique has been established previously in healthy individuals with mean values (5.27 to 7.25 L/min), bias (0.00 to 0.32 L/min) and confidence intervals (-0.88 to 0.88 L/min)  ADDIN EN.CITE 25-28. To assess whether pregnancy influenced measurement reproducibility, measurements of cardiac output were performed in duplicate in the current study in a subset of 43 women (n=13 pre-pregnancy, n=20 in second trimester and n=10 in third trimester) by asking participants to perform two rebreathing manoeuvres, 5 minutes apart, in order to allow sufficient washout of the blood soluble gas. The within-observer mean (95% CI) differences were 0.10 L/min (-0.9-1.1 L/min). The coefficient of variation between repeated readings was <6%. There was no trend for the values to vary with time during pregnancy.
Peripheral vascular resistance was calculated from the formula:
Peripheral vascular resistance (dynes.sec.cm5) = mean arterial pressure (mm Hg) × 80/cardiac output (l min−1).
All measurements were performed in duplicate by a single, trained investigator (AAM), and the mean values were used in subsequent analyses. The within- and between-observer measurement reproducibility values for the aortic augmentation index were in agreement with previously published data. ADDIN EN.CITE 18 
Ultrasound asssessment
First trimester growth was assessed by measurement of embryonic crown rump length (CRL) by serial ultrasound scans at 6–7, 8–9 and fetal CRL at 10–14 weeks of gestation from last menstrual period (LMP) in all women with a regular 28-day cycle, and where this was not the case they were scheduled from the date of the luteinizing hormone surge. The embryonic CRL was measured transvaginally at 6–7 and 8–9 weeks by placing the calipers at the outer side of the crown and rump of the embryo in a longitudinal, midsagittal section. The fetal CRL at 10–14 weeks was imaged transabdominally in a midsagittal plane with the fetal spine longitudinally in view and the maximum crown to rump length was measured to establish the gestational age. Second and third trimester growth was assessed by deriving estimated fetal weight using the Hadlock four parameter model HYPERLINK \l "_ENREF_29" \o "Hadlock, 1985 #18"  ADDIN EN.CITE <EndNote><Cite><Author>Hadlock</Author><Year>1985</Year><RecNum>18</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="eszedrza7x02a6e9vz2vsew859ppse5adtwz" timestamp="1443617919">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hadlock, F. P.</author><author>Harrist, R. B.</author><author>Sharman, R. S.</author><author>Deter, R. L.</author><author>Park, S. K.</author></authors></contributors><titles><title>Estimation of fetal weight with the use of head, body, and femur measurements--a prospective study</title><secondary-title>Am J Obstet Gynecol</secondary-title><alt-title>American journal of obstetrics and gynecology</alt-title></titles><periodical><full-title>Am J Obstet Gynecol</full-title><abbr-1>American journal of obstetrics and gynecology</abbr-1></periodical><alt-periodical><full-title>Am J Obstet Gynecol</full-title><abbr-1>American journal of obstetrics and gynecology</abbr-1></alt-periodical><pages>333-7</pages><volume>151</volume><number>3</number><keywords><keyword>Abdomen/embryology</keyword><keyword>Biometry/methods</keyword><keyword>*Body Weight</keyword><keyword>Cephalometry</keyword><keyword>Female</keyword><keyword>Femur/embryology</keyword><keyword>Fetus/*anatomy &amp; histology</keyword><keyword>Humans</keyword><keyword>Pregnancy</keyword><keyword>Prospective Studies</keyword><keyword>Ultrasonography</keyword></keywords><dates><year>1985</year><pub-dates><date>Feb 1</date></pub-dates></dates><isbn>0002-9378 (Print)&#xD;0002-9378 (Linking)</isbn><accession-num>3881966</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/3881966</url></related-urls></urls></record></Cite></EndNote>29 at 20 weeks, 22–24 weeks and 32–34 weeks gestation. This formula has been shown to have the highest correlation with birth weight HYPERLINK \l "_ENREF_30" \o "Kurmanavicius, 2004 #65"  ADDIN EN.CITE <EndNote><Cite><Author>Kurmanavicius</Author><Year>2004</Year><RecNum>65</RecNum><DisplayText><style face="superscript">30</style></DisplayText><record><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="eszedrza7x02a6e9vz2vsew859ppse5adtwz" timestamp="1456404565">65</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kurmanavicius, J.</author><author>Burkhardt, T.</author><author>Wisser, J.</author><author>Huch, R.</author></authors></contributors><auth-address>Perinatal Research Unit, Department of Obstetrics, Zurich University Hospital, Zurich, Switzerland.</auth-address><titles><title>Ultrasonographic fetal weight estimation: accuracy of formulas and accuracy of examiners by birth weight from 500 to 5000 g</title><secondary-title>J Perinat Med</secondary-title><alt-title>Journal of perinatal medicine</alt-title></titles><periodical><full-title>J Perinat Med</full-title><abbr-1>Journal of perinatal medicine</abbr-1></periodical><alt-periodical><full-title>J Perinat Med</full-title><abbr-1>Journal of perinatal medicine</abbr-1></alt-periodical><pages>155-61</pages><volume>32</volume><number>2</number><keywords><keyword>*Birth Weight</keyword><keyword>Cross-Sectional Studies</keyword><keyword>Female</keyword><keyword>*Fetal Weight</keyword><keyword>Humans</keyword><keyword>Mathematics</keyword><keyword>Observer Variation</keyword><keyword>Predictive Value of Tests</keyword><keyword>Pregnancy</keyword><keyword>Reproducibility of Results</keyword><keyword>Switzerland</keyword><keyword>Ultrasonography, Prenatal/*methods</keyword></keywords><dates><year>2004</year></dates><isbn>0300-5577 (Print)&#xD;0300-5577 (Linking)</isbn><accession-num>15085892</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/15085892</url></related-urls></urls><electronic-resource-num>10.1515/JPM.2004.028</electronic-resource-num></record></Cite></EndNote>30.
Sample size
This was a feasibility study with no data available from any previous studies thus a formal sample size calculation was not performed. We aimed to recruit 80 participants within the timescale of the study.
Statistical analyses











Out of 143 women recruited pre-conception, 70 women were nulliparous, and 35 women were multiparous with previous normal pregnancy outcome. Twenty-six women with unexplained recurrent miscarriage and 12 women with previous PE and/or FGR were also recruited.
 One-hundred and one women conceived within 18 months, of which 71 women had viable pregnancies beyond the first trimester. Five pregnancies developed subsequently developed complications (fetal chromosomal abnormalities, preeclampsia and/or FGR) and were excluded from final analyses, 2 pregnancies were excluded due to incomplete data sets, leaving 64 normal pregnancies with full longitudinal data (see recruitment flow chart in Figure 1).
The study population demographics are described in Table 1, and the results are summarised in Table 2.
Relationship between fetal growth and BW: Second to third trimester growth rate was significantly associated with BW z-score (ρ =0.56, P < 0.001). First trimester fetal growth rate was not associated with 2nd to 3rd trimester fetal growth (Spearman’s correlation coefficient ρ = 0.13, P = 0.3) nor BW z-score (Spearman’s ρ = 0.13, P = 0.3).
Relationship between pre-pregnancy to second trimester cardiovascular changes, fetal growth and BW z-score: Change in CO (0.8 ± 1.2 L/min) and CI (0.4 ± 0.6 L/min/m2) were positively related to BW z-score (CO: ρ = 0.4, P = 0.004; CI: ρ = 0.3, P= 0.02) and 2nd to 3rd trimester fetal growth (CO: ρ = 0.3, P = 0.02; CI: ρ = 0.3, P = 0.04). Reduction in PVR was significantly related to BW z-score (ρ = 0.3, P = 0.02), and showed a trend in association with 2nd to 3rd trimester fetal growth rate, but this was not significant (ρ = 0.3, P = 0.06). Reduction in AIx (:-10± 9%) was significantly associated with 2nd to 3rd trimester fetal growth rate (ρ = -0.3, P = 0.04). Pre-pregnancy to second trimester decrease in bSBP (: -5 + 8mmHg) or cSBP (: -9 + 8mm Hg) were not related to 2nd to 3rd trimester fetal growth rate (ρ = 0.07, P = 0.6 and ρ = -0.06, P = 0.7 respectively) nor BW z-score (ρ = 0.06, P = 0.6 and ρ = -0.04, P = 0.8). 
Overall, there was a significant rise in cardiac output from a pre-pregnancy value of 5.56 ± 0.94 L/min to 6.40 ± 1.09 L/min in the third trimester (P<0.001). This was independent of body surface area since there was also a significant rise in cardiac index from 3.15 ± 0.55 L/min/m2 to 3.52 ± 0.53 L/min/m2 (P<0.001). However, there was significant, inverse association between pre-pregnancy values of cardiac output and the subsequent rise during pregnancy (r=-0.59, P<0.001), which remained after adjusting for body surface area (cardiac index: r=-0.59, P<0.001). 
Of the 64 women with full longitudinal data, 11 had previous pregnancy complications (recurrent miscarriage, PE, FGR). To exclude any bias from previous abnormal obstetric outcome, we performed a sub-analysis of nulliparous and multiparous women with a previous normal pregnancy outcome (53 cases in total). The relationship between pregnancy-driven Aix remained significantly associated with delta 2nd to 3rd trimester EFW (ρ =-0.3, P = 0.02) and BW z-score (ρ =-0.3, P = 0.03). Changes in CO from pre-pregnancy to mid-pregnancy also remained significantly associated with delta 2nd to 3rd trimester EFW (ρ =0.3, P =0.05) but not to BW z-score (ρ =0.2, P = 0.07).
Discussion
We report that changes in maternal cardiovascular adaptation are related to fetal size and growth in normal pregnancy. We find an increase in CO and CI from pre-pregnancy to the second trimester. Furthermore, the increase in CO is significantly positively associated with both BW and 2nd to 3rd trimester fetal growth velocity and a reduction in PVR is associated with greater BW. Importantly, as previously reported ADDIN EN.CITE 31, the most substantial adaptations in CO and PVR occur early in the first trimester. The timing of these changes is crucial as they occur prior to the development of a functional placental unit at 12 weeks suggesting that important adaptations of maternal cardiovascular haemodynamics precede this. The findings are likely to be valid as our sample size provided 99% power to detect an observed change of 0.8±1.2L/min in cardiac output from pre-pregnancy to second trimester, at P<0.05.
We found no relationship between BP in the different trimesters of pregnancy with fetal growth or BW, however data from the prospective Generation R study ADDIN EN.CITE 32 suggests that higher BP is associated with a lower fetal weight from the third trimester. It should be noted that pregnancies with gestational hypertension and pre-eclampsia were included in their analyses, therefore lower BW may be attributable to FGR and preterm delivery, which are strongly related to both conditions.
It may be hypothesised that the relationships that we report are more pronounced in pathological pregnancies. It is important to note that this was a feasibility study in healthy pregnancies and was not powered for pathological outcomes, which occur in approximately 10% of pregnancies. 
Studies of cardiac function in pathological pregnancies report that early-onset pre-eclampsia (< 34 weeks gestation) is associated with reduced CO and high PVR; the inverse is observed in pregnancies with late-onset pre-eclampsia (>34 weeks gestation)  ADDIN EN.CITE ,,. In early-onset pre-eclampsia, there is a high likelihood of FGR whereas in late onset pre-eclampsia BW is either normal or increased ADDIN EN.CITE 10.  These observations in relation to BW are difficult to explain using the conventional placental hypothesis model of fetal growth, as the feto-placental circulation is not established until 11-12 weeks of pregnancy by which time major cardiovascular changes have happened in the mother. The findings can however be explained if CO were a key determinant of fetal growth. If validated, particularly in pathological pregnancies, the findings would underpin a rationale for early identification of women at risk of poor pregnancy outcome. It might also raise the prospect of early therapy; oral volume loading and administration of vasodilators have been observed to improve fetal growth in early-onset pre-eclampsia and FGR ADDIN EN.CITE 34.
The strength of this study is that it is the first to report pre-conception and pregnancy-induced cardiovascular changes in relation to birth weight and fetal growth velocity. In addition, parameters were measured in a longitudinal design, and therefore changes observed are more likely to reflect true variation within the cohort. A weakness of the study is the relatively small sample size, although adequately powered to observe a change of 0.8L/min in cardiac output, it is likely to be insufficient to detect smaller changes. Further, we only included analyses for normal pregnancy outcome, as the study was a feasibility study and not powered to observe changes in pathological pregnancies. There were 5 pathological pregnancy outcomes: 2 women with FGR babies before 34 weeks (one with pre-eclampsia), one each with pre-eclampsia, FGR and pre-eclampsia/FGR after 34 weeks.
In conclusion, maternal cardiovascular changes in CO and PVR in the first half of pregnancy may play an important part in determining later fetal growth and BW. There is no association between cardiovascular changes and fetal size in the second trimester, suggesting that a larger fetus in the second trimester does not in turn lead to greater cardiovascular changes in the mother. The relationships are only evident when the cardiovascular changes are compared to a woman’s baseline pre-pregnancy measures and perhaps explain why these associations had not been appreciated from studies conducted in already established pregnancy. 
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Figure 2: Summary of study protocol






















































Table 1 Demographic data of 64 participants with normal pregnancies
Demographic	All(64)
Age, years	32 ± 4
Ethnicity, Caucasian (%)	58/64(91%)
Height, m	1.65 ± 0.07
Weight, kg	69 ± 12
BMI, kg/m2	26 ± 4
Gestation at delivery, weeks	40 ± 1
Delivery BW, grams	3545 ± 554




Table 2: Cardiovascular parameters: mean values, pregnancy-induced changes and correlations with fetal growth and birth weight in 64 normal pregnancies.
Parameter	Pre-pregnancy value	Change from Pre-pregnancy to 2nd trimester	2nd to 3rd trimester growth as EFW in grams (P), significance (p)	BW in grams z-score (P), significance (p)
HR, bpm	68 ± 10	+ 8 ± 10	0.2, 0.3	0.2, 0.07
Brachial SBP, mmHg	108 ± 9	- 5 ± 8	0.07, 0.6	0.06, 0.6
Brachial DBP, mmHg	71 ± 7	- 9 ± 6	-0.05, 0.7	-0.08, 0.5
Central SBP, mmHg	99 ± 9	- 9 ± 8	-0.06, 0.7	-0.04, 0.8
MAP, mmHg	85 ± 8	- 8 ± 6	-0.08, 0.6	-0.08, 0.5
CO, L/min	5.60 ± 0.95	+ 0.8 ± 1.2	0.3, 0.02	0.4, 0.004
SV, ml	79 ± 12	+ 3 ± 14	0.2, 0.2	0.2, 0.1
CI, L/min/m2	3.18 ± 0.54	+ 0.4 ± 0.6	0.3, 0.04	0.3, 0.02
PVR, dynes.sec.cm5	1240 ± 224	- 258 ± 233	0.3, 0.06	0.3, 0.02
AIx, %	20 ± 9	- 10 ± 9	-0.3, 0.04	-0.2, 0.2
aPWV, m/sec	5.25 ± 0.62	- 0.5 ± 0.7	-0.02, 0.9	0.003, 0.9
Data are means ± SD. + denotes increase from pre-pregnancy value, - denotes decrease from pre-pregnancy value. EFW = estimated fetal weight. P = Spearman’s coefficient, p = significance.

Data excluded for pregnancy complications:
5

Full longitudinal data in normal pregnancies:
64











Lost to follow-up: 1

Total number of women recruited: 143
70 Nulliparous, 35 multiparous with previous normal pregnancies, 26 RM, 12 PE/IUGR

Early pregnancy losses: 30 
Miscarriage < 6 weeks (14)
Miscarriage > 6 weeks (12)
Ectopic pregnancy (4)

Total number of pregnancies: 101
55 nullliparous, 24 multiparous with previous normal pregnancies, 15 RM, 7 PE/IUGR












	Pregnancy outcome: Gestation, birth weight, pregnancy complications

3rd trimester 
(32 – 34 weeks)





(22 – 24 weeks)





	Ultrasound scan: Fetal growth & maternal uterine artery Doppler 
	Cardiovascular assessments

At 6-7 weeks gestation by last menstrual period (LMP), at least 2-3 weeks after first positive pregnancy test:
	Ultrasound scan for pregnancy viability, embryonic size measured by crown-rump length (two scans, two weeks apart to check serial first trimester growth)
	Cardiovascular assessments and blood tests

Daily ovulation testing - day 6 to detection of Luteinising Hormone (LH) surge followed by daily pregnancy testing - day of LH surge till three consecutive positive pregnancy test results or start of next menstrual cycle

(At least a month after stopping hormonal contraception)
	Age, ethnicity, menstrual, obstetric, cardiovascular history
	Height, weight, body mass index 
	Cardiovascular assessments
	Blood tests: Biochemistry and platelet function
	Provided digital hormone urine ovulation detection and pregnancy test kits (SPD Company Ltd)
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